| Original language | English |
|---|---|
| Pages (from-to) | 884-885 |
| Number of pages | 2 |
| Journal | The Lancet Gastroenterology and Hepatology |
| Volume | 6 |
| Issue number | 11 |
| DOIs |
|
| State | Published - Nov 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Addressing unmet needs from a new frontier of IBD : the South Asian IBD Alliance. / Aswani-Omprakash, Tina; Sharma, Vishal; Bishu, Shrinivas et al.
In: The Lancet Gastroenterology and Hepatology, Vol. 6, No. 11, 11.2021, p. 884-885.Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Addressing unmet needs from a new frontier of IBD
T2 - the South Asian IBD Alliance
AU - Aswani-Omprakash, Tina
AU - Sharma, Vishal
AU - Bishu, Shrinivas
AU - Balasubramaniam, Madhura
AU - Bhatia, Sumit
AU - Nandi, Neilanjan
AU - Shah, Neha D.
AU - Deepak, Parakkal
AU - Sebastian, Shaji
N1 - Funding Information: TA-O has received speaker fees or served as a consultant or on an advisory board for Janssen, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, Takeda, Genentech-Roche, Celgene, and Hollister. SBi has served as a consultant for Bristol Myers Squibb and AbbVie. SBh has served as consultant, received speaker fees, or been on an advisory board of Janssen, Zydus, Takeda, Ferring, Abbott, and Dr Reddy's Pharma. NN has served as a consultant, received speaker honoraria, or is on an advisory board for Janssen, AbbVie, Takeda, Pfizer, Eli Lilly, Daiichii Sankyo, Forefront Collaborative, VRIS, PriMed, ReachMD, and Imdedex. NDS is a consultant to GI on Demand with American College of Gastroenterology and Gastro Girl. PD has served as a consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, and Scipher Medicine Corporation; PD also received grants from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb–Celgene, and Boehringer Ingelheim. SS holds research grants from Biogen, Takeda, Pfizer, Janssen, AbbVie, Tillotts Pharma, Ferring, and Biohit; served on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene and Tillots Pharma; and has received speaker fees from AbbVie, Takeda, Celltrion, Pfizer, Biogen, AbbVie, Janssen, Merck, Warner Chilcott and Falk Pharma. The authors acknowledge Sharan Khela for creating figure 1 in the appendix .
PY - 2021/11
Y1 - 2021/11
UR - http://www.scopus.com/inward/record.url?scp=85118286249&partnerID=8YFLogxK
U2 - 10.1016/S2468-1253(21)00336-8
DO - 10.1016/S2468-1253(21)00336-8
M3 - Comment/debate
C2 - 34626558
AN - SCOPUS:85118286249
SN - 2468-1253
VL - 6
SP - 884
EP - 885
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
IS - 11
ER -